Growth response of human coronary smooth muscle cells to angiotensin II and influence of angiotensin AT1 receptor blockade

Coronary Artery Disease

Volumn 9, Issue 4, 1998, Pages 167-175

  Hafizi, Sassan ^a   Chester, Adrian H ^a   Allen, Sean P ^a   Morgan, Kevin ^a   Yacoub, Magdi H ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Angiotensin; Calcium; Coronary; Human; Hypertrophy; Receptors; Smooth muscle; Vascular

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; CALCIUM ION; FURA 2; LOSARTAN; LOSARTAN POTASSIUM; PERTUSSIS TOXIN; RECEPTOR SUBTYPE;

ARTERY MUSCLE; ARTICLE; BLOOD VESSEL WALL; CALCIUM CELL LEVEL; CARDIOVASCULAR DISEASE; CELL COUNT; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; DNA SYNTHESIS; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN SYNTHESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; THICKNESS;

EID: 0031838129     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199809040-00001     Document Type: Article

References (50)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature 1993; 362:801-809.
2. Bauters C, Meurice T, Hamon M, McFadden E, Lablanche J, Bertrand ME. Mechanisms and prevention of restenosis: from experimental models to clinical practice. Cardiovasc Res 1996; 31:835-846.
3. Lee RM, Owens GK, Scott Burden T, Head RJ, Mulvany MJ, Schiffrin EL. Pathophysiology of smooth muscle in hypertension. Can J Physiol Pharmacol 1995; 73:574-584.
4. Powell JS, Muller RK, Rouge M, Kuhn H, Hefti F, Baumgartner HR. The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol 1990; 16 (suppl 4): S42-S49.
5. Lee RMKW, Berecek KH, Tsoporis J, McKenzie R, Triggle CR. Prevention of hypertension and vascular changes by captopril treatment. Hypertension 1991; 17:141-150.
6. Morishita R, Higaki J, Nakamura F, Tomita N, Yu H, Nagano M, et al. Regression of hypertension-induced vascular hypertrophy by an ACE inhibitor and calcium antagonist in the spontaneously hypertensive rat. Blood Press Suppl 1992; 3:41-47.
7. Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991; 68:450-456.
8. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988; 62:749-756.
9. Berk BC, Vekshtein V, Gordon HM, Tsuda T. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989; 13:305-314.
10. Mii S, Ware JA, Mallette SA, Kent KC. Effect of angiotensin II on human vascular smooth muscle cell growth. J Surg Res 1994; 57:174-178.
11. Assender JW, Irenius E, Fredholm BB. 5-Hydroxytryptamine, angiotensin and bradykinin transiently increase intracellular calcium concentrations and PKC-α activity, but do not induce mitogenesis in human vascular smooth muscle cells. Acta Physiol Scand 1997; 160:207-217.
12. Chiu AT, Roscoe WA, McCall DE, Timmermans PBMWM. Angiotensin II-1 receptors mediate both vasoconstrictor and hypertrophic responses in rat aortic smooth muscle cells. Receptor 1991; 1:133-140.
13. Briand V, Riva L, Galzin AM. Characterization of the angiotensin II AT1 receptor subtype involved in DNA synthesis in cultured vascular smooth muscle cells. Br J Pharmacol 1994; 112:1195-1201.
14. Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE. Expression of AT2 receptors in the developing rat fetus. J Clin Invest 1991; 83:921-933.
15. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor, Nature 1991; 351:233-236.
16. Ohyama K, Yamano Y, Chaki S, Kondo T, Inagami T. Domains for G-protein coupling in angiotensin II receptor type I: studies by site-directed mutagenesis. Biochem Biophys Res Commun 1992; 189:677-683.
17. Griendling KK, Tsuda T, Berk BC, Alexander RW. Angiotensin II stimulation of vascular smooth muscle cells. Secondary signalling mechanisms. Am J Hypertens 1989; 2:659-665.
18. Kruse HJ, Bauriedel G, Heimerl J, Hofling B, Weber PC. Role of L-type calcium channels on stimulated calcium influx and on proliferative activity of human coronary smooth muscle cells. J Cardiovasc Pharmacol 1994; 24:328-335.
19. + T cells to adult human heart endothelial cells, and study of second-signal requirements. Immunology 1996; 89:220-226.
20. Weber H, Taylor DS, Molloy CJ. Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin. J Clin Invest 1994; 93:788-798.
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction Anal Biochem 1987; 162:156-159.
22. Guo DF, Furuta H, Mizukoshi M, Inagami T. The genomic organization of human angiotensin II type 1 receptor. Biochem Biophys Res Commun 1994; 200:313-319.
23. Martin MM, Elton TS. The sequence and genomic organization of the human type 2 angiotensin II receptor. Biochem Biophys Res Commun 1995; 209:554-562.
24. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260:3440-3450.
25. Hafizi S, Chester AH, Yacoub MH. Mitogenic response of cultured human coronary artery vascular smooth muscle cells (VSMC) [abstract]. Eur J Clin Invest 1996; 26:A6.
26. Dubey RK, Roy A, Overbeck HW. Culture of renal arteriolar smooth muscle cells. Mitogenic responses to angiotensin II. Circ Res 1992; 71:1143-1152.
27. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993; 91:2268-2274.
28. Liu G, Espinosa E, Oemar BS, Lüscher TF. Bimodal effects of angiotesin II on migration of human and rat smooth muscle cells. Direct stimulation and indirect inhibition via transforming growth factor-β1. Arterioscler Thromb Vasc Biol 1997; 17:1251-1257.
29. Pollman MJ, Yamada T, Horiuchi M, Gibbons GH. Vasoactive substances regulate vascular smooth muscle cell apoptosis. Countervailing influences of nitric oxide and angiotensin II. Circ Res 1996; 79:748-756.
30. Ohya Y, Sperelakis N. Involvement of a GTP-binding protein in stimulating action of angiotensin II on calcium channels in vascular smooth muscle cells. Circ Res 1991; 68:763-771.
31. Gutowski S, Smrcka A, Nowak L, Wu DG, Simon M, Sternweis PC. Antibodies to the alpha q subfamily of guanine nucleotide-binding regulatory protein alpha subunits attenuate activation of phosphatidylinositol 4,5-bisphosphate hydrolysis by hormones. J Biol Chem 1991; 266:20519-20524.
32. Hafizi S, Chester AH, Yacoub MH. Molecular mechanisms of vascular smooth muscle cell growth. Curr Opin Cardiol 1997; 12:495-503.
33. Meloche S, Seuwen K, Pages G, Pouysségur J. Biphasic and synergistic action of p44mapk (ERK1) by growth factors: correlation between late phase activation and mitogenicity. Mol Endocrinol 1992; 6:845-854.
34. Mii S, Khalil RA, Morgan KG, Ware JA, Kent KC. Mitogen-activated protein kinase and proliferation of human vascular smooth muscle cells. Am J Physiol 1996; 270:H142-H150.
35. 1 receptor: role of the p70 S6 kinase signalling pathway [abstract]. Eur Heart J 1997; 18(suppl):445.
36. Proud CG. p70 S6 kinase: an enigma with variations. Trends Biochem 1996; 21:181-185.
37. Redpath NT, Foulstone EJ, Proud CG. Regulation of translation elongation factor-2 by insulin via a rapamycin-sensitive signalling pathway. EMBO J 1996; 15:2291-2297.
38. Giasson E, Meloche S. Role of p70 S6 protein kinase in angiotensin II-induced protein synthesis in vascular smooth muscle cells. J Biol Chem 1995; 270:5225-5231.
39. Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE. Rapamycin inhibition of the 70-kilodalton S6 protein kinase. Science 1992; 257:973-977.
40. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation and signaling by the 70 kd S6 protein kinases. Cell 1992; 69:1227-1236.
41. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669-677.
42. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992; 327:685-691.
43. Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, et al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 1994; 344:910-913.
44. Benetos A, Gautier S, Ricard S, Topouchian J, Asmar R, Poirier O. et al. Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation 1996; 94:698-703.
45. Multicentre European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Circulation 1992; 86:100-110.
46. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25:1345-1350.
47. Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, et al. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991; 17:626-635.
48. Strauer BE. Ventricular function and coronary hemodynamics in hypertensive heart disease. Am J Cardiol 1979; 44:999-1006.
49. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, et al. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997; 99:278-287.
50. Regan CP, Anderson PG, Bishop SP, Berecek KH. Captopril prevents vascular and fibrotic changes but not cardiac hypertrophy in aortic-banded rats. Am J Physiol 1996; 271:H906-H913.